Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews
Authors
- Amanda M. Wilson (ORCID: https://orcid.org/0000-0003-3259-8169)
- Nana Kragh (ORCID: https://orcid.org/0000-0002-9222-4479)
- Dana Britt DiBenedetti (ORCID: https://orcid.org/0000-0003-2294-9519)
- Brigitte Pan‐Petesch (ORCID: https://orcid.org/0000-0001-9853-2635)
- Daniela Neme (ORCID: https://orcid.org/0000-0001-8905-140X)
- Tung Wynn (ORCID: https://orcid.org/0000-0002-7331-4364)
- Annemieke Willemze (ORCID: https://orcid.org/0000-0001-9348-8479)
Institutions
- RTI Health Solutions (US)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Swedish Orphan Biovitrum (Sweden) (SE)